Fluralaner (Vepripak®) for demodicosis, otodectosis, and sarcoptic mange in dogs: evaluation of efficacy and safety based on multicenter studies

Relevance. Acarosis in dogs (demodicosis, otodectosis, and sarcoptic mange) is one of the reasons for visiting a veterinarian; long-acting systemic acaricides with high compliance are important for controlling infestations and reducing the risk of re-infestation. Objective. To summarize the data on the therapeutic efficacy of Vepripak® (fluralaner, chewable tablet) in the treatment of demodicosis, otodectosis, and sarcoptic mange in dogs. Materials and methods. The data of a pilot clinical observation and a prospective multicenter open study (total 986 dogs, aged 6 months to 10 years) were analyzed, as well as a study of palatability (n=520). Vepripak® was administered orally once at a dose of 25…56 mg of fluralaner/kg of body weight; in the protocol – at least 2 hours after the last feeding. The efficacy in acarosis was assessed by the dynamics of clinical signs and microscopy (skin scrapings/ear secretions). Results. 100% therapeutic efficacy was observed in dogs with diagnosed acarosis. demodicosis, otodectosis, and sarcoptic mange: Demodex canis was not detected in scrapings after 14 days, Otodectes cynotis was not detected after 28 days, and clinical improvement in sarcoptic mange was observed after 2 to 4 weeks. In a multicenter study, no adverse events were reported during a 12-week period, and the voluntary consumption of the chewable form was 99.8%. Conclusion. Vepripak® demonstrated high clinical efficacy in a series of observations of major acaroses in dogs and high consumption, which may increase adherence to therapy in dermatological practice.